JUL 10, 2014 01:00 AM PDT

More Predictive Results in Cell-Based Assays

SPONSORED BY: PerkinElmer, PerkinElmer
  • Philip Gribbon, PhD, Chief Scientific Officer, European ScreeningPort, Hamburg, GermanyVolker Eckelt, PhD, Portfolio Director Multimode Detection, PerkinElmer, Hamburg, GermanyNorbert Garbow,
      Dr. Philip Gribbon is the Chief Scientific Officer at the European ScreeningPort (ESP), a public-private partnership based in Hamburg Germany, which works mainly with academic research institutes in the area of drug discovery. The ESP uses a range of high throughput screening (HTS) systems and assay methods and provides support for biomarker studies within clinical and pre-clinical research projects. Since the setup of the ESP, Dr. Gribbon has worked in close collaboration with leading life-science industry partners, such as PerkinElmer, to help validate novel technologies which can directly apply to projects. Previously, Dr. Gribbon has worked at Pfizer Global Research on hit discovery using HTS technologies and gained considerable experience in drug discovery across several target classes. Later, at GSK, he led a team of physicists with the remit of increasing the impact of biophysical methods on the pharmaceutical R&D process. Dr. Gribbon did his undergraduate and PhD studies at Imperial College, London and served as a post-doctoral researcher at the University of Manchester, working on how the biophysical properties of proteoglycans help define the mechanical properties of cartilage in health and disease.
      Dr. Volker Eckelt has been contributing to the field of multimode detection & plate reader technology for over 14 years in a variety of different roles, including Application Support, R&D, and Product Management. Dr. Eckelt joined PerkinElmer in 2011 and is currently responsible for product management of the Multimode Detection portfolio, which includes the new XX. Before joining PerkinElmer, Dr. Eckelt worked at Corning where he set up and managed the European Corning Epic Application Center based in Fontainebleau, France. This included label-free, fee-for-service assay development and screening for biochemical and cell-based assays. Prior to this, he was responsible for development of Corning Epic instrumentation within R&D at CyBio (Jena, Germany) in a collaboration between Corning (US) and CyBio.  He also worked as an Application Scientist at CyBio with a focus on flash luminescence, liquid handling and automation. Dr. Eckelt received his PhD in biology in 1999 at the Institute for Tropical Medicine, Hamburg, Germany.
      Dr. Norbert Garbow has been responsible for R&D Application Support for PerkinElmer's multimode detection plate readers since 2010. This includes significant contributions to customer support, instrument customizations and new product developments, such as the XX. Prior to this, Dr. Garbow worked as the Project Leader for one of PerkinElmer's High Content Screening systems, setting up product enhancements and custom-specific developments.Before joining PerkinElmer in 2007, Dr. Garbow worked at Evotec Technologies where he was involved with development of High Content Screening Instrumentation in several positions, including Product Management, Application Support, and Hardware Development. He was also involved in the development of Evotec's single molecule detection technologies. Dr. Garbow received his PhD in Physics in 1996 at the University Mainz, Germany.


    In this webinar, our expert panel of speakers will introduce the new EnSight™ Multimode Plate Reader from PerkinElmer and demonstrate how the unique combination of well-imaging with labeled and label-free detection technologies can produce more reliable readouts and generate more predictive data earlier in the drug discovery process.

    As an example, our guest speaker Dr. Philip Gribbon (European ScreeningPort, Hamburg), will discuss the use of the EnSight system in anti-cancer drug discovery, for testing cell viability and proliferation in phenotypic readouts. Dr. Gribbon will present results obtained using EnSight, comparing the use of digital phase-contrast imaging and ATP detection for routine profiling of 4 cancer cell lines against a panel of standard cytotoxic and anti-cancer compounds.

    EnSight is the first plate reader to offer cell imaging capabilities in addition to label-free, Alpha and conventional multimode detection technologies. The well-imaging technology enables users to quickly visualize cells and generate data which is intrinsically quantifiable on a per-cell basis. For instance, in complex assays where classification of rare events such as colony formation is important, combining imaging with whole well readouts is now possible. The EnSight system's advantage is its ability to extract physiologically relevant phenotypic parameters using advanced imaging methods and in the same instrument monitor target-based readouts using industry standard multimode detection technologies.

    How the EnSight system can help you to generate more predictive data earlier in the drug discovery process

    How to improve your data quality and reduce your costs in cell-based assays

    How the EnSight system's imaging capabilities make it an ideal instrument for use in anti-cancer drug discovery

    A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

    Show Resources
    Loading Comments...